NASDAQ
21.02.25
16:15 Uhr
0,430 US-Dollar
-0,010
-2,30 %
-2,30 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.01. | Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares | 11 | MarketBeat | ||
| 06.12.24 | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 226 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 08.11.24 | Athira exploring strategic alternatives after Alzheimer's failure | 10 | BioPharma Dive | ||
| 08.11.24 | Athira Pharma GAAP EPS of -$0.75 misses by $0.04 | 2 | Seeking Alpha | ||
| 07.11.24 | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 190 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 07.11.24 | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.11.24 | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | 1.032 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen | |
| 18.10.24 | Athira Pharma faces Nasdaq delisting over share price | 12 | Investing.com | ||
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 18.10.24 | Athira Pharma, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 26.09.24 | Athira Pharma-Aktie stürzt auf 52-Wochen-Tief von 0,41 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09.24 | After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule | 3 | FierceBiotech | ||
| 19.09.24 | Athira Pharma stock faces pivot and workforce cuts amid trial setback - Mizuho | 6 | Investing.com | ||
| 18.09.24 | Athira Pharma-Aktie erreicht 52-Wochen-Tief bei 0,46 US-Dollar | 7 | Investing.com Deutsch | ||
| 17.09.24 | Athira Pharma, Inc.: Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
| 17.09.24 | Athira Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.09.24 | Athira Pharma executive sells shares on clinical trial milestone | 2 | Investing.com | ||
| 06.09.24 | Athira Pharma executive sells shares worth $1,429 | 1 | Investing.com | ||
| 06.09.24 | Athira Pharma CEO sells over $2.8k in company stock | 1 | Investing.com | ||
| 06.09.24 | Athira Pharma COO Rachel Lenington sells shares worth $1,429 | 1 | Investing.com | ||
| 06.09.24 | Athira Pharma general counsel acquires shares, sells for $1.4k | 2 | Investing.com |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,976 | +2,63 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BIOXXMED | 0,920 | -3,36 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
21.02.2025 / 20:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORGANOVO | 0,355 | +1,00 % | ORGANOVO HOLDINGS, INC. - 10-Q, Quarterly Report | ||
| OCUGEN | 0,658 | +0,77 % | Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410-a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse... ► Artikel lesen | |
| INFLARX | 1,740 | -1,08 % | InflaRx holt sich 30 Millionen Dollar durch Aktienplatzierung | InflaRx hat eine Kapitalerhöhung mit einem Bruttoerlös von 30 Millionen Dollar abgeschlossen. Dabei wurden 8,25 Millionen Stammaktien zu je 2,00 Dollar ausgegeben. Zudem wurden 6,75 Millionen vorfinanzierte... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,041 | +6,58 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,730 | -6,41 % | EQS-News: Bio-Gate AG: Bio-Gate bringt über Partner weitere Produktlinie zum Schutz von Haut- und Hufarealen bei Pferden auf den Markt | EQS-News: Bio-Gate AG
/ Schlagwort(e): Produkteinführung/Vorläufiges Ergebnis
Bio-Gate bringt über Partner weitere Produktlinie zum Schutz von Haut- und Hufarealen bei Pferden... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,886 | -3,90 % | Defence Therapeutics Inc.: Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million | Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
| VAXART | 0,689 | +0,73 % | Vaxart, Inc.: Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial | Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,071 | +11,56 % | Burcon NutraScience Corporation: Burcon Announces Details of $9.43 Million Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,964 | -2,43 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,310 | +1,31 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| IMMUNIC | 1,300 | +7,79 % | EQS-News: Immunic AG: Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing | Issuer: Immunic AG
/ Key word(s): Study results
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,129 | -3,73 % | AIM ImmunoTech Highlights Higher Post-COVID Prevalence Of Myalgic Encephalomyelitis/Chronic Fatigue | WASHINGTON (dpa-AFX) - AIM ImmunoTech Inc. (AIM), Wednesday revealed 15 times increase in incidence of Myalgic encephalomyelitis or ME/ Chronic Fatigue Syndrome or CFS in patients infected with... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |
Das Unternehmen ATHIRA PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,430 Euro und damit -2,30 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.
